CA-JUNIPER-NETWORKS
NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, and Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced they have worked with Algeria Telecom, the leader in the Algerian telecommunications market, to roll out its modernized, nationwide IP metro commercial network to support current demand for increased capacity as well as future needs driven by 5G and FTTx.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005904/en/
Algeria Telecom has formed a mid-term strategic plan to implement a transport network with a homogenized, optimized topology as well as automation capabilities that guarantee bandwidth and future-proofing of its infrastructure in a growing market. NEC and Juniper have successfully delivered Algeria Telecom’s next generation IP metro network while ensuring quality of service, driving toward the best possible user experience, at scale.
As the innovative foundation of the new platform, Algeria Telecom has selected high-performing, secure solutions from the Juniper Networks portfolio for SDN-ready, cloud-grade networking and feature-rich, simple and secure connectivity at scale, deployed as access nodes to create separate pre-aggregation, aggregation and access domains for optimal reliability. Elements of the Juniper Paragon Automation cloud-native solution suite, Paragon Pathfinder and Paragon Planner have been deployed, enabling Algeria Telecom to achieve deep visibility and simplified operations of its network and services. This paves the way for assured user experiences within complex 5G and multicloud services. All of the Juniper platforms run on a single operating system, Junos® OS , to create an easily-managed, simplified and open solution.
NEC leveraged its extensive transport network integration and engineering capabilities to skillfully deliver best-in-class solutions that are dynamically tailored for Algeria Telecom’s requirements. Moreover, NEC orchestrated the total project as a ‘One-Stop Network Integrator’, capitalizing on its professional services based on global and local experiences ranging from network analysis and consulting, to design, implementation, migration and operation of high-capacity networks.
In addition, NEC and Juniper’s solid partnership, built on a track record of delivering innovative networking to hundreds of customers across the globe, has enabled the tight coordination between the parties to achieve Algeria Telecom’s objective of providing a high-capacity innovative network to accommodate surging data traffic and a future of diversified 5G use cases.
"The successful completion of the IP metro network modernization project by our partners, NEC Corporation and Juniper Networks, will allow us to make the migration to IPV6 and the initiation of digital transformation, as well as the implementation of high speed internet, as we best satisfy the needs of Algeria Telecom customers," said Mr. Adel Bentoumi, CEO of Algeria Telecom.
“The rapid growth of network traffic is a clear indication of the need for modernization and expansion of network capacity,” said Allahoum Hocine, Head of IP Core, Algeria Telecom. “NEC and Juniper have been extremely attentive to our needs, both technical and commercial, working as an extension of our team with their outstanding local engineering abilities, as well as their relentless efforts to assure quality of experience and on-time delivery. Overall, the innovative solutions from Juniper to enable this automated metro cloud architecture have helped us achieve our strategic goals and thrive as we pave the way for 5G.”
“Networks have always been a key asset for service providers, but going forward they will be the foundation for every aspect of business transformation in the 5G and cloud era. Algeria Telecom is jumping ahead of the curve by investing in an open, agile and automated network architecture that can drive simplified operations, improved economics and superior end-user experiences,” said Brendan Gibbs, Senior Vice President, Automated WAN Solutions, Juniper Networks.
“Our customer-first approach and uncompromising quality are values that are deeply ingrained in our culture,” said Hideyuki Ogata, General Manager, Service Provider Solutions Department, NEC Corporation. “This, combined with our accumulated domain expertise at NEC 5G Transport Network Center of Excellence (CoE) in EMEA, makes us confident that our extended engagement through this partnership will help enable continuous success and advancement of Algeria Telecom’s business.”
Additional Resources:
The NEC-Juniper Global Alliance
About Algeria Telecom
Algeria Telecommunications Corporation (French: Algérie Télécom) is the state owned telecom operator in Algeria. It is a public company active in the fields of fixed phone and internet. Algérie Télécom was created on 5 August 2000.
For more information, visit Algeria Telecom at www.algerietelecom.dz
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com .
LinkedIn
: https://www.linkedin.com/company/nec/
YouTube
: https://www.youtube.com/user/NECglobalOfficial
Facebook
: https://www.facebook.com/nec.global/
Twitter
: https://twitter.com/NEC_corp
NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2022 NEC Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005904/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
